SEARCH RESULTS

9 RESULTS

Reisa Sperling on Gammagard™ Misses Endpoints in Phase 3 Trial

COMMENT The IVIG results are very disappointing, as this means we are likely at least two to three years away from an approved disease-modifying therapy for AD dementia patients, as large-scale trials for other agents are still enrolling. The finding of a ...

Reisa Sperling on FDA Approves Amyvid for Clinical Use

COMMENT The approval of PET amyloid imaging for clinical use is definitely an important step forward for the field. I think PET amyloid imaging will prove useful in the clinic, especially for those difficult dementia cases—younger patients, unusual clinical ...

Current Filters

  • TYPE: Comment x
  • Commentator: Sperling, Reisa x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE